Transitions of care in anticoagulated patients

References

• AnsellJHirshJPollerLBusseyHJacobsonAHylekEThe pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest2004126204S233S15383473
   PubMed Web of Science ®Google Scholar
• Falck-YtterYFrancisCWJohansonNAAntithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e278Se325S22315265
   PubMed Web of Science ®Google Scholar
• HartRGPearceLAAguilarMIMeta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillationAnn Intern Med200714685786717577005
   PubMed Web of Science ®Google Scholar
• WhitlockRPSunJCFremesSERubensFDTeohKHAntithrombotic and thrombolytic therapy for valvular disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e576Se600S22315272
   PubMed Web of Science ®Google Scholar
• KripalaniSJacksonATSchnipperJLColemanEAPromoting effective transitions of care at hospital discharge: a review of key issues for hospitalistsJ Hosp Med2007231432317935242
   PubMed Web of Science ®Google Scholar
• BellCMRahimi-DarabadPOrnerAIDiscontinuity of chronic medications in patients discharged from the intensive care unitJ Gen Intern Med20062193794116918738
   PubMed Web of Science ®Google Scholar
• JacksonSLPetersonGMVialJHJupeDMImproving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiationJ Intern Med200425613714415257726
   PubMed Web of Science ®Google Scholar
• TjiaJBonnerABriesacherBAMcGeeSTerrillEMillerKMedication discrepancies upon hospital to skilled nursing facility transitionsJ Gen Intern Med20092463063519291332
   PubMed Web of Science ®Google Scholar
• PhillipsKWAnsellJOutpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality managementExpert Rev Cardiovasc Ther20086577018095907
   PubMedGoogle Scholar
• Arixtra® (fondaparinux sodium) product information Available from: http://us.gsk.com/products/assets/us_arixtra.pdfAccessed August 1, 2012
   Google Scholar
• Lovenox® (enoxaparin sodium) product information Available from: http://products.sanofi.us/lovenox/lovenox.htmlAccessed August 1, 2012
   Google Scholar
• Coumadin® (warfarin sodium) product information Available from: http://packageinserts.bms.com/pi/pi_coumadin.pdfAccessed August 1, 2012
   Google Scholar
• RuncimanWBRougheadEESempleSJAdamsRJAdverse drug events and medication errors in AustraliaInt J Qual Health Care200315Suppl 1i49i5914660523
   PubMed Web of Science ®Google Scholar
• GuyattGHAklEACrowtherMGuttermanDDSchuünemannHJAmerican College of Chest PhysiciansAntithrombotic Therapy and Prevention of Thrombosis Panel. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 27S47S22315257
   PubMed Web of Science ®Google Scholar
• TurpieAGFondaparinux: a Factor Xa inhibitor for antithrombotic therapyExpert Opin Pharmacother200451373138415163281
   PubMed Web of Science ®Google Scholar
• YouJJSingerDEHowardPAAntithrombotic Therapy for Atrial Fibrillation. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e531Se575S22315271
   PubMed Web of Science ®Google Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke1991229839881866765
   PubMed Web of Science ®Google Scholar
• BluesteinDYinWAffeldKJestyJFlow-induced platelet activation in mechanical heart valvesJ Heart Valve Dis20041350150815222299
   PubMed Web of Science ®Google Scholar
• YoganathanAPChandranKBSotiropoulosFFlow in prosthetic heart valves: state-of-the-art and future directionsAnn Biomed Eng2005331689169416389514
   PubMed Web of Science ®Google Scholar
• CannegieterSCRosendaalFRBrietEThromboembolic and bleeding complications in patients with mechanical heart valve prosthesesCirculation1994896356418313552
   PubMed Web of Science ®Google Scholar
• ButchartEGIonescuAPayneNGiddingsJGrunkemeierGLFraserAGA new scoring system to determine thromboembolic risk after heart valve replacementCirculation2003108Suppl 1II68II7412970211
   PubMed Web of Science ®Google Scholar
• KroegelCReissigAPrincipal mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesisRespiration20037073012584387
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAntithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guide linesChest2012141Suppl 2e419Se494S22315268
   PubMed Web of Science ®Google Scholar
• CushmanMTsaiAWWhiteRHDeep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiologyAm J Med2004117192515210384
   PubMed Web of Science ®Google Scholar
• GageBFWatermanADShannonWBoechlerMRichMWRadfordMJValidation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial FibrillationJAMA20012852864287011401607
   PubMed Web of Science ®Google Scholar
• CammAJKirchhofPLipGYGuidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Europace2010121360142020876603
   PubMed Web of Science ®Google Scholar
• FusterVRydénLECannomDSACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyCirculation2006114e257e35416908781
   PubMed Web of Science ®Google Scholar
• WannLSCurtisABEllenbogenKA2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesCirculation20111231144115021321155
   PubMed Web of Science ®Google Scholar
• DouketisJDSpyropoulosACSpencerFAPerioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e326Se350S22315266
   PubMed Web of Science ®Google Scholar
• National Quality Forum Performance Measures: Anticoagulation (0373 overlap, 043 AF/flutter, 0503 acute PE, 0581 DVT, 0593 PE > 3 mo, 0624 warfarin, 1525 chronic AC) Available from: http://www.qualityforum.org/Measures_List.aspx#p=2&s=n&so=a&k=anticoagulation&e=1&st=&sd=&mt=&cs=&ss=Accessed July 27, 2012
   Google Scholar
• Joint Commission National Patient Safety Goals: Anticoagulation Available from: http://www.jointcommission.org/search/default.aspx?Keywords=anticoagulant&f=sitename&sitename=Joint+CommissionAccessed July 27, 2012
   Google Scholar
• Joint CommissionPreventing errors Available from: http://www.jointcommission.org/search/default.aspx?Keywords=preventing+errors&f=sitename&sitename=Joint+CommissionAccessed July 27, 2012
   Google Scholar
• Center for Medicare and Medicaid ServicesSafety topics. Anticoagulation; hospital-acquired conditions Available from: https://www.premierinc.com/safety/safety-share/10-08-full-txt.jspAccessed July 27, 2012
   Google Scholar
• Center for Medicare and Medicaid ServicesPhysician Quality reporting Initiative. Anticoagulation Available from: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/index.html?redirect=/PQRI/15_MeasuresCodes.aspAccessed July 27, 2012
   Google Scholar
• NabauerMGerthALimbourgTThe Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial managementEuropace20091142343419153087
   PubMed Web of Science ®Google Scholar
• ColliAVerhoyeJPHeijmenRAntithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey resultsEur J Cardiothorac Surg20083353153618203613
   PubMed Web of Science ®Google Scholar
• AndersonFAJrHirshJWhiteKFitzgeraldRHJrTemporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee RegistryChest2003124349S356S14668417
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and QualityNational Guidelines Clearinghouse Available from: http://www.qualitymeasures.ahrq.gov/hhs-measure-inventory/browse.aspxAccessed July 27, 2012
   Google Scholar
• KripalaniSLeFevreFPhillipsCOWilliamsMVBasaviahPBakerDWDeficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of careJAMA200729783184117327525
   PubMed Web of Science ®Google Scholar
• VillanuevaTTransitioning the patient with acute coronary syndrome from inpatient to primary careJ Hosp Med20105Suppl 4S8S1420842747
   PubMed Web of Science ®Google Scholar
• SnowVBeckDBudnitzTTransitions of Care Consensus Policy Statement American College of Physicians-Society of General Internal Medicine-Society of Hospital Medicine-American Geriatrics Society-American College of Emergency Physicians-Society of Academic Emergency MedicineJ Gen Intern Med20092497197619343456
   PubMed Web of Science ®Google Scholar
• ForsterAJMurffHJPetersonJFGandhiTKBatesDWAdverse drug events occurring following hospital dischargeJ Gen Intern Med20052031732315857487
   PubMed Web of Science ®Google Scholar
• GandaraEMonizTTUngarJDeficits in discharge documentation in patients transferred to rehabilitation facilities on anticoagulation: results of a systemwide evaluationJt Comm J Qual Patient Saf20083446046318714747
   PubMedGoogle Scholar
• PradhanAALevineMAWarfarin use in atrial fibrillation: a random sample survey of family physician beliefs and preferencesCan J Clin Pharmacol2002919920212584578
   PubMedGoogle Scholar
• ArepallyGBauerKABhattDLThe use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical educationCrit Pathw Cardiol20109414820215910
   PubMedGoogle Scholar
• IngelgardAHollowellJReddyPGoldKTranKFitzmauriceDWhat are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaireJ Thromb Thrombolysis20062125726516683218
   PubMed Web of Science ®Google Scholar
• De SchryverELvan GijnJKappelleLJKoudstaalPJAlgraANon-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic strokeJ Neurol20052521316132115868068
   PubMed Web of Science ®Google Scholar
• KneelandPPFangMCCurrent issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolismPatient Prefer Adherence20104516020361065
   PubMed Web of Science ®Google Scholar
• LaneDAPonsfordJShelleyASirpalALipGYPatient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation ProjectInt J Cardiol200611035435816253356
   PubMed Web of Science ®Google Scholar
• JonasDEBryant ShillidayBLaundonWRPignoneMPatient time requirements for anticoagulation therapy with warfarinMed Decis Making20103020621619773584
   PubMed Web of Science ®Google Scholar
• JowettSBryanSMaheIA multinational investigation of time and traveling costs in attending anticoagulation clinicsValue Health20081120721218380632
   PubMed Web of Science ®Google Scholar
• McAnultyJHBarriers to the use of warfarin: potential solutionsJ Interv Card Electrophysiol200410Suppl 1172014739735
   PubMed Web of Science ®Google Scholar
• KoweyPRReiffelJAMyerburgRWarfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry)Am J Cardiol20101051130113420381665
   PubMed Web of Science ®Google Scholar
• PernodGLabarereJYverJEDUC’AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized studyJ Gen Intern Med2008231441144618566863
   PubMed Web of Science ®Google Scholar
• Hixson-WallaceJADotsonJBBlakeySAEffect of regimen complexity on patient satisfaction and compliance with warfarin therapyClin Appl Thromb Hemost20017333711190902
   PubMed Web of Science ®Google Scholar
• KamaliFWynneHPharmacogenetics of warfarinAnnu Rev Med201061637519686083
   PubMed Web of Science ®Google Scholar
• Pradaxa® (dabigatran etexilate) product information Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdfAccessed August 1, 2012
   Google Scholar
• Xarelto® (rivaroxaban) product information Available from: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100Accessed August 1, 2012
   Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med20093611139115119717844
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSReillyPAWallentinLNewly identified events in the RE-LY trialN Engl J Med20103631875187621047252
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNOral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialJ Thromb Haemost200752178218517764540
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialLancet200737094995617869635
   PubMed Web of Science ®Google Scholar
• HuoMHErikssonBIDahlOERE-NOVATE II Study GroupOral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: The RE-NOVATE II randomised trialThromb Haemost201110572172921225098
   PubMed Web of Science ®Google Scholar
• GinsbergJSDavidsonBLCompPCOral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgeryJ Arthroplasty2009241918534438
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKRE-MEDY and RE-SONATE Trials InvestigatorsExtended use of dabigatran, warfarin, or placebo in venous thromboembolismN Engl J Med201336870971823425163
   PubMed Web of Science ®Google Scholar
• LassenMRAgenoWBorrisLCRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplastyN Engl J Med20083582776278618579812
   PubMed Web of Science ®Google Scholar
• ErikssonBIBorrisLCFriedmanRJRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplastyN Engl J Med20083582765277518579811
   PubMed Web of Science ®Google Scholar
• KakkarAKBrennerBDahlOEExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trialLancet2008372313918582928
   PubMed Web of Science ®Google Scholar
• TurpieAGLassenMRDavidsonBLRivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialLancet20093731673168019411100
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med201136588389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med201136598199221870978
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med201136480681721309657
   PubMed Web of Science ®Google Scholar
• LassenMRGallusARaskobGEPineoGChenDRamirezLMApixaban versus enoxaparin for thromboprophylaxis after hip replacementN Engl J Med20103632487249821175312
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDHornickPApixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialLancet201037580781520206776
   PubMed Web of Science ®Google Scholar
• WalengaJMAdiguzelCDrug and dietary interactions of the new and emerging oral anticoagulantsInt J Clin Pract20106495696720584229
   PubMed Web of Science ®Google Scholar
• Eliquis® (apixaban) product information Available from: https://www.hcp.eliquis.com/Pagesindex.aspx Revised Dec 2012Accessed January 23, 2013
   Google Scholar
• LopesRDAlexanderJHAl-KhatibSMApixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationaleAm Heart J201015933133920211292
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationPradaxa (dabigatran etexilate mesylate): Drug safety comunication – should not be used in patients wth mechanical prosthetic heart valves Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm332949.htmAccessed 25 March, 2013
   Google Scholar